IPO registrations (S-1, F-1) · Registrants
Science 37 Holdings, Inc.
- SEC CIK
- 1819113 · filings on EDGAR ↗
- Former names
- Lifesci Acquisition II Corp. (2020–2021)
- Registration
- Form S-1, first filed 2020-10-14, last 2022-01-20; 2 initial registrations, 3 amendments
- Outcome
- Final prospectus filed 2020-11-23; declared effective 2020-11-20
- Industry (SIC)
- Services-Commercial Physical & Biological Research 8731
- Incorporated in
- DE
- Business address
- 800 PARK OFFICES DRIVE, SUITE 3606, Research Triangle Park, NC 27709
- EIN
- 84-4278203
- EDGAR entity type
- operating
- Insiders and CEO pay
- Science 37 Holdings, Inc. on the corporate pages
Offering terms
- Final price
- $0.90 per share (424B4 filed 2020-11-23)
- Shares sold
- 7,500,000
- Gross proceeds
- $6,750,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol LSAQ
- Lead underwriters
- Ladenburg Thalmann
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: Lifesci Acquisition II Corp. EXACT (CIK (EXACT))
Filings 13
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-10-14 | S-1 | S-1 (registration) | Lifesci Acquisition II Corp. | 0001104659-20-114990 ↗ |
| 2020-11-18 | S-1/A | S-1/A (amendment) | Lifesci Acquisition II Corp. | 0001104659-20-126467 ↗ |
| 2020-11-20 | EFFECT | EFFECT (declared effective) | Lifesci Acquisition II Corp. | 9999999995-20-003258 ↗ |
| 2020-11-23 | 424B4 | 424B4 (final prospectus) | Lifesci Acquisition II Corp. | 0001104659-20-128486 ↗ |
| 2020-11-23 | 424B4 | 424B4 (final prospectus) | Lifesci Acquisition II Corp. | 0001104659-20-128489 ↗ |
| 2021-09-23 | EFFECT | EFFECT (declared effective) | Lifesci Acquisition II Corp. | 9999999995-21-003640 ↗ |
| 2021-11-05 | S-1 | S-1 (registration) | Science 37 Holdings, Inc. | 0001104659-21-135047 ↗ |
| 2021-12-27 | S-1/A | S-1/A (amendment) | Science 37 Holdings, Inc. | 0001104659-21-153297 ↗ |
| 2022-01-20 | S-1/A | S-1/A (amendment) | Science 37 Holdings, Inc. | 0001104659-22-006016 ↗ |
| 2022-01-25 | EFFECT | EFFECT (declared effective) | Science 37 Holdings, Inc. | 9999999995-22-000219 ↗ |
| 2022-04-20 | EFFECT | EFFECT (declared effective) | Science 37 Holdings, Inc. | 9999999995-22-001037 ↗ |
| 2023-03-08 | EFFECT | EFFECT (declared effective) | Science 37 Holdings, Inc. | 9999999995-23-000541 ↗ |
| 2023-03-13 | EFFECT | EFFECT (declared effective) | Science 37 Holdings, Inc. | 9999999995-23-000572 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-11-18 | S-1/A | registration statement | $10.00 | 7,500,000 | $75,000,000 | Nasdaq LSAQ | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ | |
| 2020-11-23 | 424B4 | final prospectus | $0.90 | 7,500,000 | $6,750,000 | Nasdaq LSAQ | 1 | primary document; price sentence, shares headline, proceeds computed, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Barrett Elizabeth A. | Director | 1 | 2020 | ||
| Dobkin David | Director,Officer | Chief Financial Officer | 1 | 2020 | |
| Graham G. Walmsley | Director | 1 | 2020 | ||
| Janssen Scott | Director | 1 | 2020 | ||
| LifeSci Holdings LLC | TenPercentOwner | 3 | 2020–2021 | ||
| Mathers Thomas P. | Director | 1 | 2020 | ||
| McDonald Andrew I | Director,Officer,TenPercentOwner | Chief Executive Officer | 3 | 2020–2021 | |
| Rice Michael Yehuda | Director,Officer,TenPercentOwner | Chief Operating Officer | 3 | 2020–2021 | |
| wynn Thomas Joseph III | Director | 1 | 2020 | ||
| Coman David | Director,Officer; Officer; Officer,Other | CEO and Director; Chief Executive Officer | 8 | 2021–2024 | |
| Cotliar Jonathan | Officer | Chief Medical Officer | 10 | 2021–2024 | |
| Faulkner Robert C. | Director; Other | 5 | 2021–2024 | ||
| Forman Darcy | Officer | Chief Delivery Officer | 9 | 2021–2024 | |
| Geffon Steven | Officer | Chief Commercial Officer | 5 | 2021–2022 | |
| Goulburn Adam | Director | 4 | 2021–2022 | ||
| Green Jeremy | Director,TenPercentOwner; Other; TenPercentOwner | 8 | 2021–2024 | ||
| Hubbard John W | Director; Officer; Other | Director | 6 | 2021–2024 | |
| Pellizzari Christine A | Officer | Chief Legal and HR Officer; Chief Legal Officer | 11 | 2021–2024 | |
| Redmile Group, LLC | Director,TenPercentOwner; Other | 8 | 2021–2024 | ||
| Rollins Emily | Director; Other | 5 | 2021–2024 | ||
| Zaranek Mike | Officer | Chief Financial Officer | 8 | 2021–2024 | |
| Tiwari Neil | Director; Other | 5 | 2021–2024 | ||
| De Silva Bhooshitha B. | Director | 1 | 2021 | ||
| Eagle Holding Co II, LLC | TenPercentOwner | 3 | 2021–2024 | ||
| Hebert Peter | TenPercentOwner | 2 | 2021–2022 | ||
| Jaguar Holding Co II | TenPercentOwner | 3 | 2021–2024 | ||
| Jaguar Holding Co I, LLC | TenPercentOwner | 3 | 2021–2024 | ||
| Lux Capital Management, LLC | TenPercentOwner | 2 | 2021–2022 | ||
| Lux Co-Invest Opportunities, L.P. | TenPercentOwner | 2 | 2021–2022 | ||
| Lux Co-Invest Partners, LLC | TenPercentOwner | 2 | 2021–2022 | ||
| Lux Venture Partners IV, LLC | TenPercentOwner | 2 | 2021–2022 | ||
| Lux Ventures IV, L.P. | TenPercentOwner | 2 | 2021–2022 | ||
| PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | TenPercentOwner | 3 | 2021–2024 | ||
| PPD, Inc. | TenPercentOwner | 3 | 2021–2024 | ||
| Wildcat Acquisition Holdings (UK) Ltd | TenPercentOwner | 3 | 2021–2024 | ||
| Wolfe Josh | TenPercentOwner | 2 | 2021–2022 | ||
| THERMO FISHER SCIENTIFIC INC. | TenPercentOwner | 5 | 2021–2024 | ||
| Thermo Fisher Scientific Powder US Holdings Corp. | TenPercentOwner | 3 | 2021–2024 | ||
| Shipton Michael | Officer | Chief Commercial Officer | 6 | 2022–2024 | |
| von Autenried Paul | Director; Other | 4 | 2022–2024 | ||
| Bryenton Troy | Officer | Chief Technology Officer | 2 | 2023 | |
| Fisher Scientific International LLC | TenPercentOwner | 2 | 2024 | ||
| Fisher Scientific Worldwide Inc. | TenPercentOwner | 2 | 2024 | ||
| Spectra-Physics Holdings USA, LLC | TenPercentOwner | 2 | 2024 | ||
| Thermo Fisher Scientific Powder Holdings I | TenPercentOwner | 2 | 2024 | ||
| Thermo Fisher Scientific Powder Holdings II | TenPercentOwner | 2 | 2024 | ||
| Thermo Fisher Scientific Powder Holdings III | TenPercentOwner | 2 | 2024 | ||
| Thermo Fisher Scientific Powder Holdings IV | TenPercentOwner | 2 | 2024 | ||
| Thermo Fisher Scientific Powder US Holdings Ltd | TenPercentOwner | 2 | 2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | Science 37 Holdings, Inc. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Services-Commercial Physical & Biological Research, NC first:
- Icoria, Inc. NC
- INVERESK RESEARCH GROUP INC NC
- PRA International, LLC NC
- IQVIA HOLDINGS INC. NC
- Icagen, Inc. NC
- Syneos Health, Inc. NC
- PRA Health Sciences, Inc. NC
- PPD, Inc. NC
- WEED, INC. AZ
- GLYCOTEX, INC. C3
In other datasets, the same topic (Medical research) in NC:
- Form D issuer: 22nd Century Group, Inc. (Form D private offerings)
- Nonprofit: 3000 MILES FOR AUTISM (Nonprofits (IRS Form 990))
Interests: Services-Commercial Physical & Biological Research · Medical research